No. Actually, the AstraZeneca doses are being arranged through a consortium out of Oxford Biomedica and Cobra Biologics, separate from that 2018 investment.
Sir John Bell, the Regius professor of medicine at Oxford and the developer of the vaccine, spoke on this—he's Canadian, by the way, from Alberta—to Evan Solomon. I highly recommend that you watch that interview. That is what we should have done.